Clinical trials
Hypertrophic Cardiomyopathy (HCM) clinical trials
Below are recruiting hypertrophic cardiomyopathy (hcm) clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Anchorage, AlaskaAges 18 years+ - NCT07420907Recruiting
Tracking heart health over time
This study uses a wearable patch to monitor heart-related signs in people with heart conditions. It aims to learn more about how these conditions progress, which could help improve future care.
Chicago, IllinoisAges 18 years+ - NCT06433050RecruitingEarly Phase 1
Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03846297Recruiting
Decision support for defibrillator placement in hypertrophic cardiomyopathy
This trial looks at how to make better decisions about whether someone with hypertrophic cardiomyopathy (HCM) should get an implantable heart defibrillator. It may help by using structured decision support to guide defibrillator implantation.
Boulogne-Billancourt, Hauts-de-SeineAges 16 years+ - NCT04265040Recruiting
Heart muscle disease registry for non-ischemic conditions
This trial is a registry, meaning it collects health information to help doctors study heart muscle diseases and plan future cardiovascular studies. You may be able to join if you have a non-ischemic cardiomyopathy such as dilated cardiomyopathy, certain forms of thick heart muscle, non-compaction, or arrhythmogenic right-sided disease.
Heidelberg, Baden-WurttembergAges 18–80 - NCT06607471Recruiting
Study on non-ischemic heart muscle diseases
This study looks at different types of heart muscle diseases that are not caused by blocked arteries (non-ischemic cardiomyopathies). It aims to better understand how to diagnose, predict outcomes, and treat these conditions by gathering information from many patients over time.
Milan, MilanoAges 18 years+ - NCT06813443Recruiting
Studying cardiomyopathy to find who needs a heart transplant
This study is looking at people with cardiomyopathy to understand which patients are most in need of a heart transplant. By joining, you will help doctors learn more about critical cases and improve care for heart muscle disease.
Bologna, Emilia-Romagna/BolognaAges 12 years+ - NCT06935253Recruiting
AI to Improve Cardiology Care
This trial tests whether large language models (a type of AI that understands human language) can help cardiologists give better care. If you are a qualified cardiologist who currently treats patients, you may be eligible.
Palo Alto, CaliforniaAges 18 years+ - NCT07006493Recruiting
Radiofrequency ablation for obstructive hypertrophic cardiomyopathy
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT07202897RecruitingPhase 3
Preventing blood clots in hypertrophic cardiomyopathy with rivaroxaban
This trial tests if the blood thinner rivaroxaban can prevent strokes in people with hypertrophic cardiomyopathy who have early signs of damage in their left atrium (the heart's upper chamber). You may qualify if you have this condition, are in a normal heart rhythm, and are between 40 and 80 years old.
AngersAges 40–80 - NCT07263204Recruiting
AI for diagnosing and predicting hypertrophic cardiomyopathy
This trial uses artificial intelligence to help diagnose and predict outcomes for people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes thickened. It may help doctors better understand your condition and plan your care.
Hangzhou, ZhejiangAges 18 years+ - NCT07344480Recruiting
Study on heart disease in children with RASopathy
This study looks at medical records of children with a genetic condition called RASopathy who developed thickened heart muscle and needed hospital care for heart failure in their first six months of life. The goal is to understand how the heart condition progresses over time.
MünchenAges Any age - NCT07354646Recruiting
Understanding heart disease with T1 mapping MRI
This study uses a special type of MRI (T1 mapping) to better understand different heart conditions. It may help doctors improve diagnosis and treatment by looking at detailed images of your heart muscle.
Beijing, Beijing MunicipalityAges Any age - NCT07359690Recruiting
Study of Heart Muscle Biopsies
This study collects samples of heart muscle tissue (biopsy) to better understand heart conditions. It is for people who already need this biopsy for their healthcare.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07372196Recruiting
Left bundle branch pacing after myectomy for hypertrophic cardiomyopathy
This trial is testing a new way to pace the heart (left bundle branch pacing) for people with hypertrophic cardiomyopathy who still have a dangerous heart rhythm problem after myectomy surgery. It aims to see if this pacing can reduce the risk of sudden cardiac death.
Novosibirsk, Novosibirsk OblastAges 18–75 - NCT07381894Recruiting
Hypertrophic cardiomyopathy patient registry
This registry collects information about people with hypertrophic cardiomyopathy (HCM) to better understand the condition and improve care. It is for patients who have a confirmed HCM diagnosis not caused by other issues.
ManchesterAges 18–99 - NCT07382128Recruiting
Heart MRI to Understand Hypertrophic Cardiomyopathy
This trial uses a special heart MRI to better understand different types of hypertrophic cardiomyopathy (thick heart muscle). It may help doctors tell apart various forms of the condition and guide treatment.
Bologna, BOAges 18 years+ - NCT02413450Enrolling by invitation
Using patient DNA cells to study inherited heart rhythm risks
This study uses your blood or genetic information to make “iPS cells,” lab-grown cells that can help researchers study inherited heart rhythm problems like LQTS, Brugada syndrome, CPVT, or early repolarization syndrome. It may help improve understanding of why these rhythms happen and guide future treatments.
Baltimore, MarylandAges 18–85 - NCT07557498Recruiting
Mavacamten Outcomes and Experiences in Heart Muscle Disease
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Bollington, MacclesfieldAges 18 years+ - NCT07595354Recruiting
Safe Exercise Plan for Young People at Risk of Heart Disease
This study helps children and teens who may be at risk for a heart condition called HCM learn safe ways to exercise. Researchers will create a personalized exercise plan and check in regularly to see how it goes.
LiverpoolAges 10–18 - NCT07600177RecruitingPhase 4
Switching Heart Medicines: Mavacamten to Aficamten
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
Kansas City, MissouriAges 18–90 - NCT07336290Enrolling by invitation
One-stop MRI for hypertrophic cardiomyopathy
This study uses a single, advanced heart MRI to get a complete picture of hypertrophic cardiomyopathy—a condition where the heart muscle is thickened. It aims to make diagnosis and treatment planning faster and easier for patients.
Ages Any age - NCT07295613Enrolling by invitation
Registry of hypertrophic cardiomyopathy: regional features, genetics and course
This study is a registry that collects information about people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) to better understand how it affects different people and to study its genetic causes. By joining, you help researchers learn more about this condition and how it progresses.
Moscow, Moscow RegAges Any age - NCT06683872Enrolling by invitation
CT heart modeling for hypertrophic obstructive cardiomyopathy
This trial uses a special CT scan to create a 3D model of your heart's blood flow. It aims to see if this model can help doctors better predict how well treatments work for people with a thick heart muscle that blocks blood flow.
Hangzhou, ZhejiangAges 18–70
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hypertrophic cardiomyopathy (hcm)?
- Yes. Clin2 currently lists 42 recruiting hypertrophic cardiomyopathy (hcm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hypertrophic cardiomyopathy (hcm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hypertrophic cardiomyopathy (hcm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.